Granada Gold Mine Inc. press release
Axcan announces conference call and web cast for first quarter of fiscal 2006 results
TSXV - TSX Venture Exchange · Gold · Silver · Rubidium · Scandium · Cesium · Neodymium · Gallium · Hafnium · Strontium · Cerium · Rare Earth Elements · Magnet Rare Earth Elements · Canada
TSX SYMBOL (Toronto Stock Exchange): AXP NASDAQ SYMBOL (Nasdaq National Market): AXCA
MONT SAINT-HILAIRE, QC, Feb. 2 /CNW Telbec/ - Axcan Pharma Inc. ("Axcan" or the "Company") today announced that it will report financial results for the fiscal quarter of fiscal 2006, ended December 31, 2005, on Thursday, February 9, 2006, after the close of market. Axcan will host a conference call at 8:30 A.M. ET, on Friday, February 10, 2006. Interested parties may also access the conference call by web cast at www.axcan.com. The web cast will be archived for 90 days. The telephone numbers to access the conference call are (866) 250-4910 (Canada and United States) or (416) 644-3425 (international). A replay of the call will be available until February 17, 2006. The telephone number to access the replay of the call is (416) 640-1917 code: 21174075.
Axcan is a leading specialty pharmaceutical company involved in the field of gastroenterology. The Company markets a broad line of prescription products sold for the treatment of symptoms in a number of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to cystic fibrosis. Axcan's products are marketed by its own sales force in North America and Europe. Its common shares are listed on the Toronto Stock Exchange under the symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA and other regulatory approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Canadian Multijurisdictional Disclosure System.